- Gus Cairns | 07 April 2011
A
study published at the Conference on Retroviruses and Opportunistic Infections (CROI 2011) in February has found that
patients starting therapy who either have viral loads over 100,000 copies/ml,
or who have a ...
- Gus Cairns | 29 March 2011
Very high levels of adherence have been achieved in one of
the ongoing randomised controlled trials of oral pre-exposure prophylaxis
(PrEP), according to a poster presentation at last month’s Conference on Retroviruses ...
- Gus Cairns | 25 March 2011
Two studies presented at
last month’s 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) both found that gay men diagnosed
with HIV considerably reduce the amount of sex they have that ...
- Keith Alcorn | 10 March 2011
Just over one-quarter of gay men with HIV successfully
treated for acute hepatitis C infection became reinfected with hepatitis C
within two years, almost all with a different genotype, Amsterdam doctors
reported last ...
- Gus Cairns | 09 March 2011
This
time last year, at the 17th Conference on Retroviruses and Opportunistic Infections (CROI), Dr Moupali
Das of the San Francisco Department of Public Health presented
evidence to show that the city’s intensive ...
- Gus Cairns | 09 March 2011
A study of patients in
southern Africa diagnosed during primary HIV
infection has found that one in five maintained viral loads over 100,000
copies/ml for at least 400 days after infection. One in ...
- Keith Alcorn | 07 March 2011
Long-term HIV infection
is the only significant factor associated with thickening of the
carotid intima media, a marker for atherosclerosis, a French
case-control study has reported.
A strong
anti-inflammatory response also appears to reduce the ...
- Carole Leach-Lemens | 07 March 2011
Use
of a lopinavir/ritonavir (LPV/r) based regimen compared to a
nevirapine-based regimen in infants not exposed to single-dose
nevirapine (sdNVP) was superior and the differences for viral
failure, drug discontinuation and death at six ...
- Carole Leach-Lemens | 07 March 2011
Extending the use of daily infant nevirapine to six months reduced the risk of
breastfeeding mother-to-child transmission by a significant 76% in
HIV-positive mothers with CD4 cell counts over 350 and not ...
- Gus Cairns | 03 March 2011
A prevention study in which the intervention being tested
failed is turning out to be a fertile source of information about HIV
transmission risk in heterosexuals.
Three substudies from the Partners
in Prevention ...
- Gus Cairns | 03 March 2011
As well as two models
of how PrEP/microbicides would impact on HIV prevalence and incidence in a
southern African context (see Forecasters
agree PrEP/microbicides could cut HIV infections in South Africa), two
mathematical models ...
- Gus Cairns | 03 March 2011
Several
presentations at the Eighteenth Conference on Retroviruses and Opportunistic Infections this week used
mathematical modelling to forecast the impact of adopting oral pre-exposure
prophlyaxis (PrEP) or a topical microbicide in a high-prevalence ...
- Liz Highleyman | 03 March 2011
Once-daily
dosing of the integrase inhibitor raltegravir (Isentress)
was found to be inferior to twice-daily dosing for treatment-naive
patients in the QDMRK study, even though most people receiving either
dose were able to suppress ...
- Keith Alcorn | 03 March 2011
Signals warning of the
transmission of drug-resistant HIV are growing in low- and
middle-income countries, and governments should step up surveillance
efforts as they scale up treatment, experts concluded today at the
Eighteenth Conference ...
- Liz Highleyman | 02 March 2011
The
experimental hepatitis C virus (HCV) protease inhibitor telaprevir,
used with pegylated interferon plus ribavirin, produced good
virological response in the first study of HIV/HCV co-infected
individuals, according to interim data presented on Wednesday ...
- Gus Cairns | 02 March 2011
The first head-to-head trial directly comparing the
acceptability of tenofovir pills and tenofovir microbicide gel amongst HIV-negative
women has found that, while African women liked both products equally,
three-quarters of US women preferred ...
- Liz Highleyman | 02 March 2011
Immune recovery and T-cell restoration may play a key role in bone loss
that occurs very soon after starting antiretroviral therapy, according to a
small study presented on Tuesday at the
18th Conference ...
- Gus Cairns | 02 March 2011
Near-perfect
adherence to oral pre-exposure prophylaxis – taking HIV drugs to prevent HIV – may
be achievable in the right settings, the Eighteenth Conference on Retroviruses and Opportunistic Infections heard
yesterday.
Participants
from the ...
- Keith Alcorn | 02 March 2011
The US Food and Drug
Administration has found no evidence of an association between
abacavir treatment and increased risk of myocardial infarction (heart
attack) in a meta-analysis of 26 randomised trials of the ...
- Liz Highleyman | 02 March 2011
HIV-positive people who lose muscle mass in their arms and legs whilst
gaining abdominal fat have a higher likelihood of death, according to
findings from the FRAM study presented on Tuesday at
the ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...